Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...